Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $16.20 billion. The enterprise value is $20.09 billion.
| Market Cap | 16.20B |
| Enterprise Value | 20.09B |
Important Dates
The last earnings date was Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.38 million shares outstanding. The number of shares has decreased by -2.55% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.38M |
| Shares Change (YoY) | -2.55% |
| Shares Change (QoQ) | +1.17% |
| Owned by Insiders (%) | 1.18% |
| Owned by Institutions (%) | 60.75% |
| Float | 60.65M |
Valuation Ratios
The trailing PE ratio is 19.74 and the forward PE ratio is 19.09.
| PE Ratio | 19.74 |
| Forward PE | 19.09 |
| PS Ratio | 4.15 |
| Forward PS | 3.59 |
| PB Ratio | 2.85 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.58 |
| P/OCF Ratio | 17.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.11, with an EV/FCF ratio of 23.04.
| EV / Earnings | 24.47 |
| EV / Sales | 5.15 |
| EV / EBITDA | 15.11 |
| EV / EBIT | 15.61 |
| EV / FCF | 23.04 |
Financial Position
The company has a current ratio of 2.18, with a Debt / Equity ratio of 0.94.
| Current Ratio | 2.18 |
| Quick Ratio | 2.17 |
| Debt / Equity | 0.94 |
| Debt / EBITDA | 3.97 |
| Debt / FCF | 6.14 |
| Interest Coverage | 7.66 |
Financial Efficiency
Return on equity (ROE) is 14.96% and return on invested capital (ROIC) is 10.72%.
| Return on Equity (ROE) | 14.96% |
| Return on Assets (ROA) | 8.48% |
| Return on Invested Capital (ROIC) | 10.72% |
| Return on Capital Employed (ROCE) | 11.49% |
| Weighted Average Cost of Capital (WACC) | 6.69% |
| Revenue Per Employee | $1.26M |
| Profits Per Employee | $265,868 |
| Employee Count | 3,088 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 15.82 |
Taxes
In the past 12 months, Genmab has paid $213.00 million in taxes.
| Income Tax | 213.00M |
| Effective Tax Rate | 20.60% |
Stock Price Statistics
The stock price has increased by +39.10% in the last 52 weeks. The beta is 0.70, so Genmab's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +39.10% |
| 50-Day Moving Average | 27.02 |
| 200-Day Moving Average | 29.01 |
| Relative Strength Index (RSI) | 45.58 |
| Average Volume (20 Days) | 1,935,667 |
Short Selling Information
The latest short interest is 8.50 million, so 1.40% of the outstanding shares have been sold short.
| Short Interest | 8.50M |
| Short Previous Month | 7.93M |
| Short % of Shares Out | 1.40% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.49 |
Income Statement
In the last 12 months, Genmab had revenue of $3.90 billion and earned $821.00 million in profits. Earnings per share was $13.11.
| Revenue | 3.90B |
| Gross Profit | 3.64B |
| Operating Income | 1.29B |
| Pretax Income | 1.03B |
| Net Income | 821.00M |
| EBITDA | 1.33B |
| EBIT | 1.29B |
| Earnings Per Share (EPS) | $13.11 |
Balance Sheet
The company has $1.53 billion in cash and $5.35 billion in debt, with a net cash position of -$3.83 billion or -$62.33 per share.
| Cash & Cash Equivalents | 1.53B |
| Total Debt | 5.35B |
| Net Cash | -3.83B |
| Net Cash Per Share | -$62.33 |
| Equity (Book Value) | 5.68B |
| Book Value Per Share | 92.57 |
| Working Capital | 1.40B |
Cash Flow
In the last 12 months, operating cash flow was $902.00 million and capital expenditures -$30.00 million, giving a free cash flow of $872.00 million.
| Operating Cash Flow | 902.00M |
| Capital Expenditures | -30.00M |
| Depreciation & Amortization | 43.00M |
| Net Borrowing | 5.42B |
| Free Cash Flow | 872.00M |
| FCF Per Share | $14.21 |
Margins
Gross margin is 93.31%, with operating and profit margins of 32.99% and 21.05%.
| Gross Margin | 93.31% |
| Operating Margin | 32.99% |
| Pretax Margin | 26.51% |
| Profit Margin | 21.05% |
| EBITDA Margin | 34.09% |
| EBIT Margin | 32.99% |
| FCF Margin | 22.35% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.55% |
| Shareholder Yield | 2.55% |
| Earnings Yield | 5.07% |
| FCF Yield | 5.38% |
Analyst Forecast
The average price target for Genmab is $39.56, which is 49.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $39.56 |
| Price Target Difference | 49.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 9.48% |
| EPS Growth Forecast (5Y) | 10.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 2.72 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.72 |
| Piotroski F-Score | 4 |